{"filing":{"accession_number":"0001575872-26-000504","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"rdy0920_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000504/rdy0920_6k.htm"},"events":[{"id":18062,"run_id":16215,"accession_number":"0001575872-26-000504","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit is a conference call transcript disclosing a material manufacturing and supply issue with semaglutide, a key product. Dr. Reddy's identified an out-of-specification impurity in the scaled-up API manufacturing process, requiring a halt to commercial supplies for approximately three months (until late October/early November 2026) while validation is repeated. The CEO explicitly states this will result in a temporary delay to commercial supplies and a write-down of inventory at OneSource. This is a material operational/supply disruption affecting a major product, though it does not fit neatly into the specific event categories (not a restatement, impairment charge, or workforce reduction per se, but rather a manufacturing/quality issue with supply consequences). The domain is clearly operational rather than financial, governance, legal, or existential.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16764,"accession_number":"0001575872-26-000504","item_number":"EX-99.1","item_title":"rdy0920_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a conference call transcript disclosing a material manufacturing and supply issue with semaglutide, a key product. Dr. Reddy's identified an out-of-specification impurity in the scaled-up API manufacturing process, requiring a halt to commercial supplies for approximately three months (until late October/early November 2026) while validation is repeated. The CEO explicitly states this will result in a temporary delay to commercial supplies and a write-down of inventory at OneSource. This is a material operational/supply disruption affecting a major product, though it does not fit neatly into the specific event categories (not a restatement, impairment charge, or workforce reduction per se, but rather a manufacturing/quality issue with supply consequences). The domain is clearly operational rather than financial, governance, legal, or existential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:46:40.347745+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16764,"accession_number":"0001575872-26-000504","item_number":"EX-99.1","item_title":"rdy0920_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a conference call transcript disclosing a material manufacturing and supply issue with semaglutide, a key product. Dr. Reddy's identified an out-of-specification impurity in the scaled-up API manufacturing process, requiring a halt to commercial supplies for approximately three months (until late October/early November 2026) while validation is repeated. The CEO explicitly states this will result in a temporary delay to commercial supplies and a write-down of inventory at OneSource. This is a material operational/supply disruption affecting a major product, though it does not fit neatly into the specific event categories (not a restatement, impairment charge, or workforce reduction per se, but rather a manufacturing/quality issue with supply consequences). The domain is clearly operational rather than financial, governance, legal, or existential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:46:40.347745+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-15"}]}